SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin’s arm receives USFDA approval for SUPRAX Oral Suspension, 500 mg/5mL

22 Feb 2013 Evaluate

Pharma major, Lupin’s subsidiary - Lupin Pharmaceuticals Inc has received approval for SUPRAX (Cefixime) for Oral Suspension, 500 mg/5mL from the United States Food and Drugs Administration (FDA). Lupin expects to commence shipping the product in the near future.

The approval will expand Lupin’s range of SUPRAX dosage forms available to treat approved indications in appropriate patients. SUPRAX is currently available as 100mg/5mg and 200mg/5mL suspensions; 400mg tablets as well as chewable tables 100 & 200mg.

This new drug application provides for a new strength, 500mg/5mL of SUPRAX (Cefixime) for Oral Suspension for the treatment of otitis, acute exacerbation of chronic bronchitis, uncomplicated urinary tract infections, uncomplicated gonorrhea (cervical/urethral) and pharyngitis/tonsillitis.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

Lupin Share Price

2342.15 -25.65 (-1.08%)
25-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.15
Dr. Reddys Labs. 1350.00
Cipla 1440.30
Zydus Lifesciences 1101.50
Lupin 2342.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: